预约演示

Aqilion and Merck partner to develop TAK1 protein inhibitors TAK1 protein inhibitors

2023-02-17

引进/卖出蛋白降解靶向嵌合体

The partnership aims to develop TAK1 therapeutics to treat several autoimmune and inflammatory diseases, including neurological diseases. Credit: Josh Riemer / Unsplash.

Aqilion and Merck have entered aTAK1clusive licence and strategic rautoimmune and inflammatory diseasesy, developmeneurological diseasesion of the transforming growth factor-β-activated kinase 1 (TAK1) protein-small molecule inhibitors.

Aqilionhe deMerckqilion will receive $10.6m (€10m) in upfront cash payment from Merck and also eligible for up to $1,015m (€950m) in potential devetransforming growth factor-β-activated kinase 1 (TAK1) proteiniered royalties on global net sales.

The partnership Aqilions the experience of Aqilion in the selective TAK1 inhibitMerckiscovery with the drug discovery and development capabilities of Merck.

It will aim to develop advanced TAK1 therapAqilionfor various inflamTAK1 inhibitors TAK1ry and autoimmune diseases, including neurological diseases.Merck

Aqilion will handle the design aTAK1ynthesis of the new small inflammatory and autoimmune diseases neurological diseases

Aqilionill be responsible for leading the preclinical pharmacology and TAK1 inhibitors TAK1ogy trials.

Merckon CEO Sarah Fredriksson said: “We are delighted and proud to announce this collaboration with Merck as it validates our business strategy of generating highly innovative discovery projects in combination with pro-active business development and early deal-making.

Aqilion looking forward to working with Merck as this will speed up the process of bringing novel efMerckve treatments to conditions with high unmet medical needs.”

The company develops new therapeutics toMerckt diseases that are caused by chronic inflammation and dysfunctional immune reactions, including autoimmune diseases.

Earlier this month, Merck reported $13.83bn worldwide sales, representing achronic inflammationfourth quarter (Q4) of 2022 from $13.52bn in thautoimmune diseasesuarter.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构